Harnessing the power of T cell measurement

Boulder Diagnostics

Oxford Immunotec Global PLC (NASDAQ: OXFD), a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology, has acquired substantially all of the assets of Boulder Diagnostics Inc. Oxford Immunotec will be continuing the development of three products, previously being worked on by Boulder Diagnostics, and acquired as a result of this asset purchase.

  • Spirofind®: An assay to assist in the diagnosis of Lyme disease in both early and late-presenting forms.
  • Goutifind™: An assay to assist in the diagnosis of Gout, obviating diagnosis by joint puncture.
  • Stratokine™: An assay to help select biologics for autoimmune disease based on monitoring and prognosis of drug response.

For more information on the acquisition, please click here.